Journal: Thrombosis research

Article Title: A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban.

doi: 10.1016/j.thromres.2024.01.017

Figure Lengend Snippet: Fig. 1. Relationship between the prothrombin time (PT) values and the concentrations of the three rivaroxaban.

Article Snippet: A pool of normal platelet poor plasma (NPPP) was obtained with the following characteristics: platelet count 6*109/L, prothrombin time ([PT], Dade® Innovin®, Siemens Healthcare Diagnostics, Marburg, Germany) 10.8 s, activated partial thromboplastin time ([aPTT], Dade® Actin® FS, Siemens Healthcare Diagnostics, Germany) 27.1 s, rivaroxaban anti-Xa (Biophen® Heparin LRT with Biophen® Rivaroxaban Plasma Calibrator, Hyphen BioMed, Neuville-sur-Oise, France) lower than the limit of detection (<30 ng/ml).

Techniques:

Journal: Thrombosis research

Article Title: A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban.

doi: 10.1016/j.thromres.2024.01.017

Figure Lengend Snippet: Fig. 2. Relationship between the activated partial thromboplastin time (aPTT) values, measured with Actin® FS (panel A) and Actin® FSL (panel B), and the concentrations of the three rivaroxaban.

Article Snippet: A pool of normal platelet poor plasma (NPPP) was obtained with the following characteristics: platelet count 6*109/L, prothrombin time ([PT], Dade® Innovin®, Siemens Healthcare Diagnostics, Marburg, Germany) 10.8 s, activated partial thromboplastin time ([aPTT], Dade® Actin® FS, Siemens Healthcare Diagnostics, Germany) 27.1 s, rivaroxaban anti-Xa (Biophen® Heparin LRT with Biophen® Rivaroxaban Plasma Calibrator, Hyphen BioMed, Neuville-sur-Oise, France) lower than the limit of detection (<30 ng/ml).

Techniques:

Journal: Thrombosis research

Article Title: A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban.

doi: 10.1016/j.thromres.2024.01.017

Figure Lengend Snippet: Fig. 3. Relationship between the diluted Russell viper venom time (dRVVT) screen (panel A), dRVVT confirm (panel B) values, lupus anticoagulant (LA) ratio (panel C), Actin® FSL: Actin® FS ratio (panel D) and the concentrations of the three rivaroxaban.

Article Snippet: A pool of normal platelet poor plasma (NPPP) was obtained with the following characteristics: platelet count 6*109/L, prothrombin time ([PT], Dade® Innovin®, Siemens Healthcare Diagnostics, Marburg, Germany) 10.8 s, activated partial thromboplastin time ([aPTT], Dade® Actin® FS, Siemens Healthcare Diagnostics, Germany) 27.1 s, rivaroxaban anti-Xa (Biophen® Heparin LRT with Biophen® Rivaroxaban Plasma Calibrator, Hyphen BioMed, Neuville-sur-Oise, France) lower than the limit of detection (<30 ng/ml).

Techniques:

Journal: Thrombosis research

Article Title: A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban.

doi: 10.1016/j.thromres.2024.01.017

Figure Lengend Snippet: Fig. 4. Relationship between the thrombin time (TT) values and the concentrations of the three rivaroxaban.

Article Snippet: A pool of normal platelet poor plasma (NPPP) was obtained with the following characteristics: platelet count 6*109/L, prothrombin time ([PT], Dade® Innovin®, Siemens Healthcare Diagnostics, Marburg, Germany) 10.8 s, activated partial thromboplastin time ([aPTT], Dade® Actin® FS, Siemens Healthcare Diagnostics, Germany) 27.1 s, rivaroxaban anti-Xa (Biophen® Heparin LRT with Biophen® Rivaroxaban Plasma Calibrator, Hyphen BioMed, Neuville-sur-Oise, France) lower than the limit of detection (<30 ng/ml).

Techniques:

Journal: Thrombosis research

Article Title: A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban.

doi: 10.1016/j.thromres.2024.01.017

Figure Lengend Snippet: Fig. 5. Relationship between the Clauss Fibrinogen (panel A) and prothrombin time (PT)-derived Fibrinogen (panel B) values and the concentrations of the three rivaroxaban.

Article Snippet: A pool of normal platelet poor plasma (NPPP) was obtained with the following characteristics: platelet count 6*109/L, prothrombin time ([PT], Dade® Innovin®, Siemens Healthcare Diagnostics, Marburg, Germany) 10.8 s, activated partial thromboplastin time ([aPTT], Dade® Actin® FS, Siemens Healthcare Diagnostics, Germany) 27.1 s, rivaroxaban anti-Xa (Biophen® Heparin LRT with Biophen® Rivaroxaban Plasma Calibrator, Hyphen BioMed, Neuville-sur-Oise, France) lower than the limit of detection (<30 ng/ml).

Techniques: Derivative Assay

Journal: Thrombosis research

Article Title: A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban.

doi: 10.1016/j.thromres.2024.01.017

Figure Lengend Snippet: Fig. 6. Relationship between the one-stage FVII (panel A), FVIII (panel B) and FIX (panel C) values and the concentrations of the three rivaroxaban.

Article Snippet: A pool of normal platelet poor plasma (NPPP) was obtained with the following characteristics: platelet count 6*109/L, prothrombin time ([PT], Dade® Innovin®, Siemens Healthcare Diagnostics, Marburg, Germany) 10.8 s, activated partial thromboplastin time ([aPTT], Dade® Actin® FS, Siemens Healthcare Diagnostics, Germany) 27.1 s, rivaroxaban anti-Xa (Biophen® Heparin LRT with Biophen® Rivaroxaban Plasma Calibrator, Hyphen BioMed, Neuville-sur-Oise, France) lower than the limit of detection (<30 ng/ml).

Techniques:

Journal: Thrombosis research

Article Title: A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban.

doi: 10.1016/j.thromres.2024.01.017

Figure Lengend Snippet: Fig. 7. Relationship between the Chromogenic FVIII (panel A) and FIX (panel B) values and the concentrations of the three rivaroxaban.

Article Snippet: A pool of normal platelet poor plasma (NPPP) was obtained with the following characteristics: platelet count 6*109/L, prothrombin time ([PT], Dade® Innovin®, Siemens Healthcare Diagnostics, Marburg, Germany) 10.8 s, activated partial thromboplastin time ([aPTT], Dade® Actin® FS, Siemens Healthcare Diagnostics, Germany) 27.1 s, rivaroxaban anti-Xa (Biophen® Heparin LRT with Biophen® Rivaroxaban Plasma Calibrator, Hyphen BioMed, Neuville-sur-Oise, France) lower than the limit of detection (<30 ng/ml).

Techniques:

Journal: Thrombosis Journal

Article Title: Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial

doi: 10.1186/s12959-017-0158-9

Figure Lengend Snippet: Baseline laboratory parameters of all included patients

Article Snippet: Rivaroxaban levels were also measured on the BCSxp using a chromogenic assay calibrated for rivaroxaban (BIOPHEN® DiXa-I, CoaChrom Diagnostica, Neuville-sur-Oise, France).

Techniques:

Journal: Thrombosis Journal

Article Title: Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial

doi: 10.1186/s12959-017-0158-9

Figure Lengend Snippet: Means of rivaroxaban levels from V1 to V10 for all included patients. Lowest rivaroxaban levels are indicated as 20 ng ml −1 , because a lower level is not detectable

Article Snippet: Rivaroxaban levels were also measured on the BCSxp using a chromogenic assay calibrated for rivaroxaban (BIOPHEN® DiXa-I, CoaChrom Diagnostica, Neuville-sur-Oise, France).

Techniques:

Journal: Thrombosis Journal

Article Title: Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial

doi: 10.1186/s12959-017-0158-9

Figure Lengend Snippet: Correlations between rivaroxaban concentrations and blood coagulation parameters

Article Snippet: Rivaroxaban levels were also measured on the BCSxp using a chromogenic assay calibrated for rivaroxaban (BIOPHEN® DiXa-I, CoaChrom Diagnostica, Neuville-sur-Oise, France).

Techniques: Coagulation, FIBTEM Assay

Journal: Thrombosis Journal

Article Title: Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial

doi: 10.1186/s12959-017-0158-9

Figure Lengend Snippet: Correlations between means of rivaroxaban plasma levels and various coagulation parameters from V1 to V10. Significantly ( p < 0.05 for all) correlated parameters were ( a ) thrombin generation lag time (t lag , linear approximation for t lag = 23.63 + 0.19*x, r = 0.924, p < 0.001); ( b ) thrombin generation time to peak (t max , linear approximation for t max = 63.02 + 0.34*x, r = 0.903, p < 0.001); ( c ) EXTEM clotting time (CT EXTEM , linear approximation for CT = 65.312 + 0.26*x, r = 0.926, p < 0.001) and ( d ) thromboelastometry FIBTEM time to maximum velocity (MaxV-t FIBTEM , linear approximation for MaxV-t FIBTEM = 79.132 + 0.205*x, r = 0.887, p < 0.001). Strength of correlation was interpreted by evaluating the correlation coefficient: r 0.9–1.0, very strong correlation; r 0.7–0.89, strong correlation; r 0.5–0.69, moderate correlation; r 0.3–0.49, weak correlation

Article Snippet: Rivaroxaban levels were also measured on the BCSxp using a chromogenic assay calibrated for rivaroxaban (BIOPHEN® DiXa-I, CoaChrom Diagnostica, Neuville-sur-Oise, France).

Techniques: Coagulation, FIBTEM Assay

Journal: Thrombosis research

Article Title: A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban.

doi: 10.1016/j.thromres.2024.01.017

Figure Lengend Snippet: Fig. 1. Relationship between the prothrombin time (PT) values and the concentrations of the three rivaroxaban.

Article Snippet: The concentration of each formulation was measured twice with the chromogenic anti-Xa assay (Biophen® Heparin LRT, Hyphen BioMed, Neuville-sur-Oise, France) using a rivaroxaban specific calibrator (Biophen® Rivaroxaban Plasma Calibrator, Hyphen BioMed, Neuville-sur-Oise, France).

Techniques:

Journal: Thrombosis research

Article Title: A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban.

doi: 10.1016/j.thromres.2024.01.017

Figure Lengend Snippet: Fig. 2. Relationship between the activated partial thromboplastin time (aPTT) values, measured with Actin® FS (panel A) and Actin® FSL (panel B), and the concentrations of the three rivaroxaban.

Article Snippet: The concentration of each formulation was measured twice with the chromogenic anti-Xa assay (Biophen® Heparin LRT, Hyphen BioMed, Neuville-sur-Oise, France) using a rivaroxaban specific calibrator (Biophen® Rivaroxaban Plasma Calibrator, Hyphen BioMed, Neuville-sur-Oise, France).

Techniques:

Journal: Thrombosis research

Article Title: A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban.

doi: 10.1016/j.thromres.2024.01.017

Figure Lengend Snippet: Fig. 3. Relationship between the diluted Russell viper venom time (dRVVT) screen (panel A), dRVVT confirm (panel B) values, lupus anticoagulant (LA) ratio (panel C), Actin® FSL: Actin® FS ratio (panel D) and the concentrations of the three rivaroxaban.

Article Snippet: The concentration of each formulation was measured twice with the chromogenic anti-Xa assay (Biophen® Heparin LRT, Hyphen BioMed, Neuville-sur-Oise, France) using a rivaroxaban specific calibrator (Biophen® Rivaroxaban Plasma Calibrator, Hyphen BioMed, Neuville-sur-Oise, France).

Techniques:

Journal: Thrombosis research

Article Title: A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban.

doi: 10.1016/j.thromres.2024.01.017

Figure Lengend Snippet: Fig. 4. Relationship between the thrombin time (TT) values and the concentrations of the three rivaroxaban.

Article Snippet: The concentration of each formulation was measured twice with the chromogenic anti-Xa assay (Biophen® Heparin LRT, Hyphen BioMed, Neuville-sur-Oise, France) using a rivaroxaban specific calibrator (Biophen® Rivaroxaban Plasma Calibrator, Hyphen BioMed, Neuville-sur-Oise, France).

Techniques:

Journal: Thrombosis research

Article Title: A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban.

doi: 10.1016/j.thromres.2024.01.017

Figure Lengend Snippet: Fig. 5. Relationship between the Clauss Fibrinogen (panel A) and prothrombin time (PT)-derived Fibrinogen (panel B) values and the concentrations of the three rivaroxaban.

Article Snippet: The concentration of each formulation was measured twice with the chromogenic anti-Xa assay (Biophen® Heparin LRT, Hyphen BioMed, Neuville-sur-Oise, France) using a rivaroxaban specific calibrator (Biophen® Rivaroxaban Plasma Calibrator, Hyphen BioMed, Neuville-sur-Oise, France).

Techniques: Derivative Assay

Journal: Thrombosis research

Article Title: A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban.

doi: 10.1016/j.thromres.2024.01.017

Figure Lengend Snippet: Fig. 6. Relationship between the one-stage FVII (panel A), FVIII (panel B) and FIX (panel C) values and the concentrations of the three rivaroxaban.

Article Snippet: The concentration of each formulation was measured twice with the chromogenic anti-Xa assay (Biophen® Heparin LRT, Hyphen BioMed, Neuville-sur-Oise, France) using a rivaroxaban specific calibrator (Biophen® Rivaroxaban Plasma Calibrator, Hyphen BioMed, Neuville-sur-Oise, France).

Techniques:

Journal: Thrombosis research

Article Title: A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban.

doi: 10.1016/j.thromres.2024.01.017

Figure Lengend Snippet: Fig. 7. Relationship between the Chromogenic FVIII (panel A) and FIX (panel B) values and the concentrations of the three rivaroxaban.

Article Snippet: The concentration of each formulation was measured twice with the chromogenic anti-Xa assay (Biophen® Heparin LRT, Hyphen BioMed, Neuville-sur-Oise, France) using a rivaroxaban specific calibrator (Biophen® Rivaroxaban Plasma Calibrator, Hyphen BioMed, Neuville-sur-Oise, France).

Techniques:

Journal: Research and Practice in Thrombosis and Haemostasis

Article Title: Abstract

doi: 10.1002/rth2.12125

Figure Lengend Snippet: TABLE 1 Observed concentrations in relation to targeted values in absolute numbers (mean of three measurements)

Article Snippet: BIOPHEN FVIII:C was compared with the one‐stage assay using Actin FS and Factor VIII deficient plasma (Siemens, Germany) and with another chromogenic automated assay (COAMATIC Factor VIII, CROMOGENIX on ACL TOP analyzer; Instrumentation Laboratory, Italy).

Techniques: